Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct;11(5):779-781.
doi: 10.21037/hbsn-22-322.

Providing meaningful survival benefit to hepatocellular carcinoma patients: combination therapy of future

Devanand Sarkar  1
Affiliations
Editorial

Providing meaningful survival benefit to hepatocellular carcinoma patients: combination therapy of future

Devanand Sarkar. Hepatobiliary Surg Nutr. 2022 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-22-322/coif). The author has no conflicts of interest to declare.

Comment on

References

    1. Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res 2021;149:1-61. 10.1016/bs.acr.2020.10.001 - DOI - PMC - PubMed
    1. Zhang T, Merle P, Wang H, et al. Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr 2021;10:180-92. 10.21037/hbsn-2021-7 - DOI - PMC - PubMed
    1. Chakraborty E, Sarkar D. Emerging therapies for hepatocellular carcinoma (HCC). Cancers 2022;14:2798. 10.3390/cancers14112798 - DOI - PMC - PubMed
    1. Pfister D, Nunez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450-6. 10.1038/s41586-021-03362-0 - DOI - PMC - PubMed
    1. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013;19:329-36. 10.1038/nm.3089 - DOI - PMC - PubMed